SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)*

Kymera Therapeutics, Inc.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☑ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Atlas Venture Fund X, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,384,685.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,384,685.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,384,685.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 2.9 %
12	Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons ATLAS VENTURE ASSOCIATES X, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,384,685.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,384,685.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,384,685.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐

11	Percent of class represented by amount in row (9) 2.9 %
12	Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Atlas Venture Associates X, LLC		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 2,384,685.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 2,384,685.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,384,685.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 2.9 %		
12	Type of Reporting Person (See Instructions) OO		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Atlas Venture Opportunity Fund I, L.P.
2	Check the appropriate box if a member of a Group (see instructions)

	☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 462,856.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 462,856.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 462,856.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 0.6 %
12	Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Atlas Venture Associates Opportunity I, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 462,856.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power

		462,856.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 462,856.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.6 %	
12	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Atlas Venture Associates Opportunity I, LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 462,856.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 462,856.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 462,856.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.6 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Kymera Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

500 North Beacon Street, 4th Floor, WATERTOWN, MA, 02472.

Item 2.

(a) Name of person filing:

This Schedule 13G is filed by (i) Atlas Venture Fund X, L.P., a Delaware limited partnership ("Atlas X"), (ii) Atlas Venture Associates X, L.P., a Delaware limited partnership ("AVA X LP"), (iii) Atlas Venture Associates X, LLC, a Delaware limited liability company ("AVA X LLC" and together with Atlas X and AVA X LP, the "Fund X Reporting Persons"), (iv) Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership ("AVO I"), (v) Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership ("AVAO LP") and (vi) Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company ("AVAO LLC" and together with AVO I and AVAO LP, the "Opportunity Fund Reporting Persons" and together with the Fund X Reporting Persons, the "Reporting Persons").

(b) Address or principal business office or, if none, residence:

300 Technology Square, 8th Floor Cambridge, Massachusetts 02139

(c) Citizenship:

Each of Atlas X, AVA X LP, AVO I and AVAO LP is a Delaware limited partnership. Each of AVA X LLC and AVAO LLC is a Delaware limited liability company.

(d) Title of class of securities:

COMMON STOCK, $0.0001 PAR VALUE

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

Atlas X is the record owner of 2,384,685 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X. AVO I is the record owner of 462,856 shares of Common Stock. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVO I, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVO I. As such, each of AVO I, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVO I.

(b) Percent of class:

Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 2.9% and 0.6%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 83,150,618 outstanding shares of Common Stock of the Issuer as of July 31, 2026, as reported in the Issuer's 10-Q, filed with the Securities and Exchange Commission on August 5, 2026. Collectively, the Reporting Persons beneficially own an aggregate of 2,847,541 shares of Common Stock, which represents 3.4% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13G shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

None of the Reporting Persons have the sole power to direct the vote of the Common Stock.

(ii) Shared power to vote or to direct the vote:

Each Fund X Reporting Person shares power to vote or direct the vote of 2,384,685 shares of Common Stock and each Opportunity Fund Reporting Person shares power to vote or direct the vote of 462,856 shares of Common Stock.

(iii) Sole power to dispose or to direct the disposition of:

Sole power to dispose or to direct the disposition of: None of the Reporting Persons have the sole power to dispose or to direct the disposition of the Common Stock.

(iv) Shared power to dispose or to direct the disposition of:

Each Fund X Reporting Person shares power to dispose or to direct the disposition of 2,384,685 shares of Common Stock and each Opportunity Fund Reporting Person shares power to dispose or to direct the disposition of 462,856 shares of Common Stock.

Item 5. Ownership of 5 Percent or Less of a Class.

☑ Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Atlas Venture Fund X, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates X, L.P., its GP, By: Atlas Venture Associates X, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

ATLAS VENTURE ASSOCIATES X, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates X, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

Atlas Venture Associates X, LLC

Signature:	/s/ Ommer Chohan
Name/Title:	Ommer Chohan, CFO

Date: 08/13/2026

Atlas Venture Opportunity Fund I, L.P.

Signature: /s/ Ommer Chohan
Name/Title: By: Atlas Venture Associates Opportunity I, L.P., its GP, By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date: 08/13/2026

Atlas Venture Associates Opportunity I, L.P.

Signature: /s/ Ommer Chohan
Name/Title: By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date: 08/13/2026

Atlas Venture Associates Opportunity I, LLC

Signature: /s/ Ommer Chohan
Name/Title: Ommer Chohan, CFO
Date: 08/13/2026

Exhibit Information

99.1 Joint Filing Agreement (Incorporated by reference to Exhibit A to the Schedule 13G/A, filed with the Securities and Exchange Commission on February 14, 2023)